HemoGenyx Pharmaceuticals
HemoGenyx Pharmaceuticals PLC. is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned US operating subsidiary, HemoGenyx LLC, located in Brooklyn, New York at its state- of- the- art research facility (“HemoGenyx”). For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risk of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is used only as a last resort and its use is restricted. Hemogenyx’s technology has the potential to enable many more patients suffering from devastating blood diseases, such as leukemia and lymphoma, as well as severe autoimmune diseases, such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation. HemoGenyx is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx is developing two distinct and complementary products, as well as a platform technology that it uses as an engine for novel product development.
The chairman recently recieved the Tang prize.The Tang Prize in Biopharmaceutical Science recognizes original biopharmaceutical or biomedical research that has led to significant advances towards preventing, diagnosing, and/or treating major human diseases to improve human health.
Numerous deals and projects underway including the production of a covid 19 test kit that can tell if you are a high or low risk patient if you are infected. There is talk of a take over and the financial director and his wife recently bought over 430k shares.
Please vote to get this stock added ASAP huge growth ahead!
https://www2.deloitte.com/content/dam/Deloitte/global/Documents/Finance/gx-finance-next-generation-therapies.pdf - This has caused alot of excitement, largely page 8 where it details what other companies have been paid for licencing deals. Our CDX deal with Global Co feels around the 1-3billion mark if you look at similar technologies and target market. Also page 47 seems to imply Orgenesis have either acquired or attempting to acquire Hemogenyx-Cell SA. but this may just refer to the licencing deal…
Here are some comparisons:
The similarities between https://sangamo.com/technology/cell-therapy… and https://hemogenyx.com/technology/ are striking. Per: https://www2.deloitte.com/content/dam/Deloitte/global/Documents/Finance/gx-finance-next-generation-therapies.pdf… Sangamo got £220m upfront, £3.545b total for 2 therapies. Hemogenyx has HEMO-CAR-T, ApbHC, Hu-PHEC, CDX, Covid19 Test
Potential take over: https://www.reuters.com/article/us-usa-healthcare-jpmorgan-eli-lilly/eli-lilly-targets-quarterly-deals-of-1-billion-5-billion-in-2020-cfo-idUSKBN1ZF2YJ This got tweeted and retweeted by Vlad, nobody has said officially this is going to happen, just rumour and speculation, however they want to make acquisitions of 1-5bn small pharma with early stage cancer treatments. They are suspected also of being Global Co. If it happens and your a share holder when its announced…
yeah down to much to sell, will wait for some good news
